Business Standard

Covid-19: Gilead targets 2 million remdesivir courses by year-end

The company also said it planned to start trials of an easier-to-use inhaled version of the antiviral drug, currently administered only intravenously

remdesivir, coronavirus
Premium

Remdesivir is at the forefront in the fight against the virus after the drug helped shorten hospital recovery times in a clinical trial

Press Trust of India
Gilead Sciences Inc expects supply of its potential Covid-19 drug remdesivir to exceed two million courses by year-end, the company said on Monday, more than double its previous target of 1 million.
The company also said it planned to start trials of an easier-to-use inhaled version of the antiviral drug, currently administered only intravenously, by August.
Remdesivir is at the forefront in the fight against the virus after the drug helped shorten hospital recovery times in a clinical trial.

But producing and supplying billions of doses remain major concerns as the fast-spreading respiratory illness overwhelms healthcare systems around the world.
"We will

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jun 22 2020 | 10:20 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com